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Abstract
Maintaining opiate addicts on opiates has a long history.The idea to prescribe pharmaceutical morphine as a substitute for
street heroin started in USA and was abolished on the basis of prohibitionist legislation. A new approach to maintain opiate
addicts on substitution therapy was initiated in USA in 1963, with the prescription of methadone. This approach found,
although slowly, increasing acceptance, and is nowadays considered to be a cornerstone in the management of opiate dependence
and for the prevention of HIV/AIDS in opiate injectors. Since 1975, the concept of heroin maintenance treatment was
re-activated in order to reach out to treatment-resistant heroin addicts. Research projects were performed in Switzerland, the
Netherlands,Germany,Spain,Canada and in England,another one is planned in Belgium.Based on the unanimously positive
outcomes, heroin maintenance has become routine treatment for otherwise untreatable heroin addicts in Switzerland, the
Netherlands,Germany and England,and Denmark has set up heroin maintenance without new research trials. [Uchtenhagen
AA. Heroin maintenance treatment: From idea to research to practice. Drug Alcohol Rev 2011;30:130–137]
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The origins
Prescribing and using opiates as an effective medica-
tion for a range of ailments goes back to the origins of
Chinese, Sumeric and Egyptian medicine, and prob-
ably beyond. In Homeric times, opium in wine
(‘Nepenthes’) was offered against all evils, and the
opium-made ‘Theriak’ was still considered to be the
most essential drug at the dawn of modern medicine
by Paracelsus. It was inevitable that its addictive
potential had to become manifest, but we do not
know when and where opiate addiction was first
observed and when the use of opiates as a mainte-
nance regime started. We do know however, that the
Roman emperor Marcus Aurelius was maintained
on opium by the eminent Galenus, and that the
Mughal emperor Jahangir received opium mainte-
nance. And far into the 20th century, opium dispens-
ing was practised in some countries like Pakistan and
Laos, providing dependent people with their daily
dose.
Once heroin (diacetylmorphine) was developed in
1874, it was again used as an effective medication for
many conditions, frequently prescribed as ‘patent medi-
cines’. In Europe, it was also considered to be a cure for
morphine, cocaine and opium dependence, until its
own addictive potential became obvious. In the USA,
44 narcotic clinics were set up, most of them after the
Harrison Act, which left the dependent persons without
supply, and introduced tapering off morphine for
detoxification purposes. But then, the maintenance
concept was re-invented, based on the frequency of
relapses (the ‘Tennessee system’ of 1914, see [1]).While
the southern clinics, treating mainly iatrogenic mor-
phine dependents, were quite successful, the NewYork
clinics failed in maintaining young heroin addicts from
minority groups [1,2].
Prohibition against maintenance
While all US narcotic clinics, successful or not, were
closed by law in 1923, a few doctors continued to
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prescribe heroin or morphine to addicts until the Single
Convention of 1961, when heroin became a controlled
substance and its use restricted to scientific purposes
[2]. The concept of maintaining patients on an other-
wise illegal or unwelcome consumption was incompat-
ible with the puritan idea of prohibition.
The one country resisting the temptation of a strict
prohibition in Europe was the UK where the Rolleston
Committee in 1926 recommended heroin prescribing
for chronic addicts (which at the time were mainly
socially integrated iatrogenic morphine dependents).
During the late 1950s, the number of heroin addicts
increased and their characteristics changed. As a con-
sequence, drug dependence clinics were opened in
London, and addicts receiving prescriptions had to be
notified to the Home Office. The much debated objec-
tives were medical care and at the same time social
control of addicts. For many reasons, heroin prescrib-
ing was more and more replaced by methadone
prescribing, until the AIDS epidemic led to a reconsid-
eration and new experimentation with injectable and
smokable heroin, now in a perspective of public health
interests [3].
The failure of prohibition to change habits in use of
a preferred substance became obvious in the case of
alcohol prohibition; it took much longer to realise that
the heroin epidemic in the second half of the 20th
century could not be stopped by prohibitive law
enforcement.
The revival of agonist prescribing: ‘fighting fire
with fire’
It was again in North America where agonist mainte-
nance treatment of opiate addicts was re-introduced,
using methadone instead of diamorphine, on the basis
of its advantages (oral application, longer half-life).
According to the needs of the new target population—
mainly marginalised urban heroin injectors—a compre-
hensive health and social support program went along
with methadone prescribing, in contrast to just handing
out prescriptions for unsupervised use. The model was
pioneered by Halliday in Canada in 1959 [4], followed
in 1964 with a much better known trial by Dole and
Nyswander in New York [5].
The positive effects of this new approach, especially
on the health and delinquency of patients, as was con-
firmed by an increasing number of evaluation studies,
led to a slowly growing acceptance of the maintenance
concept, in spite of ‘abstinence-only’ arguments and
opposition. But the decisive factor to speed up metha-
done (and buprenorphine) maintenance was the
advent of the HIV epidemic. Drug injecting was rec-
ognised as one major factor for transmitting the virus
infection (for hepatitis C as well).Throughout Europe,
the idea of maintaining heroin addicts on opioids
became increasingly acceptable, instead of restricting
treatment to ‘abstinence-only’ approaches. In 2003,
there were 462 412 patients in substitution treatment
[6], and the number increased to an estimated 650 000
in 2007 [7]. By 2007, substitution treatment is avail-
able in all Member States of the EU; in nine countries,
it is open to nearly all heroin addicts, and in seven
more countries to the majority of them [7]. Finally, in
2006 the World Health Organisation (WHO) suc-
ceeded in putting methadone and buprenorphine on
the list of essential medicines. While earlier the main
objective had been to reduce criminality and to curb
the illegal heroin market, this was replaced by a major
public health concern [8].
The quest for prescribing the ‘original drug’:
new research
The increasing number of methadone patients led
inevitably to an increased though still smaller number
of ‘methadone-resistant’ patients who continued to
inject heroin in spite of the availability of adequate
methadone dosages and care. At the same time, the
HIV epidemic made it a priority to increase coverage,
that is, to reach out to as many injectors as possible. In
this circumstance, the ides of prescribing heroin as
the original and preferred substance of addicts was
raised.
Even if the AIDS epidemic is at the origin of all
initiatives to prescribe heroin in Switzerland, the
Netherlands, Germany, Canada and Spain, the revival
of the idea of heroin maintenance had come up before
and was ready to be taken up again. The debate
started in Canada in the early 1950s and again in the
1970s in the Netherlands and in the USA. The argu-
ments mainly focused on heroin addiction as a
chronic condition and the need to restrict its negative
health and social consequences. Three attempts to
start heroin prescribing in US cities have not suc-
ceeded [3]. Non-medical options providing heroin to
addicts in the Netherlands (tolerated ‘home dealers’
and ‘heroin bars’) were started, but then considered to
be failures [3]. The only project under medical control
was a compromise between new thinking and political
concerns: the Amsterdam morphine prescription
experiment for highly problematic heroin addicts,
starting 1983 [9].
In the UK, where pharmaceutical diamorphine as a
substitute for street heroin was gradually replaced by
methadone after the early 1970s, and where a first
randomised trial comparing injectable heroin with
methadone had produced ambiguous results [10], a
new experiment in prescribing heroin ‘reefers’ was suc-
cessfully implemented [11]. Feasibility studies on
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heroin prescribing were initiated in Australia [12,13].
Large scale experimental studies were finally set up in
Switzerland (1994–1996), the Netherlands (1995–
1997), Germany (2002–2005), in Spain (2003–2004),
in England (2005–2009) and in Canada (2005–2008).
Belgium decided to start a trial. One has also been
prepared but not started in France, and Denmark
implemented heroin-assisted treatment in 2009
without a research project of its own.
The Swiss cohort study and the WHO
expert report
Serious attempts to engage in new scientific research on
the feasibility and effects of heroin prescribing started
as a response to the challenge of unmanageable and
intolerable open drug scenes (‘needle parks’) in major
Swiss cities.The project of heroin-assisted treatment for
addicts who failed in conventional treatments, includ-
ing methadone maintenance, was one element in a new
national drug policy, aiming at investing massively in
prevention, treatment, harm reduction and law enforce-
ment. Restoring public order, curbing drug-related
delinquency and prostitution were as important as
relieving the misery of addicts living in these public
places. However, the idea was not only to engage in new
initiatives, but also to gain solid scientific evidence, as a
basis for future policy decisions. Evidence-based policy
was asked for, in a context of controversial ideological
debates.
The Swiss 3 year project was originally designed as a
randomised controlled study comparing injectable
heroin to injectable morphine and methadone. Because
of frequent histamine-like side effects, patients could
not be recruited for the morphine and methadone arms
as planned. The design of the main study had to be
adapted to a prospective cohort study, but including a
number of randomised controlled sub-studies compar-
ing i.v. (intravenous) heroin to i.v. morphine, compar-
ing patients receiving i.v. heroin to patients on a waiting
list, pilot studies on diverse diamorphine preparations
for alternative routes of administration [14] and studies
comparing self-report data on delinquency with police
data [15,16].The study results were first published as a
monograph in 1999 [17]. A more recent study tested
the safety and effectiveness of oral (slow release and
instant release) diamorphine tablets, as a replacement
of heroin reefers for patients unable or unwilling to
inject [18].
The detailed positive results, acknowledged by an
international expert committee set up by WHO [19],
could nevertheless not separate the effects of heroin
prescribing from the effects of concomitant care. This
became the starting point for the randomised con-
trolled trials, thereby adding essential new findings to
the already established positive outcomes. In the UK a
similar new approach has started, in contrast to the
earlier practice of handing out prescriptions without an
evaluation.
The randomised controlled trials
In the Netherlands, a randomised controlled study
co-prescribing injectable or inhalable heroin in addi-
tion to oral methadone, in comparison with oral
methadone alone, started in 1995.The inhalable appli-
cation (‘chasing the dragon’) had to be considered
because the majority of Dutch heroin users prefer it
over injecting.
Trial participants were recruited from existing
methadone maintenance programs, attending their
program regularly and receiving at least 50 mg (inhal-
ing trial) or 60 mg (injecting trial) methadone per day.
The number of participants in the trials was 549, with
375 receiving inhalable heroin and 174 receiving inject-
able heroin. Altogether, 237 were randomised into the
control groups and 119 into a comparison group start-
ing out with oral methadone and transferred to inhal-
able heroin after 12 months [20].
The co-prescription of heroin in the two experimen-
tal groups lasted for 12 months.The dose of heroin was
a maximum of 1000 mg per day, plus a maximum of
150 mg of oral methadone in the experimental groups,
and a maximum of 150 mg of oral methadone per day
in the control group. After termination of the
co-prescription of heroin, all patients received oral
methadone only. All groups were provided with ancil-
lary standard psychosocial treatment [20,21].
Treatment response was significantly (P = 0.0001)
higher in the experimental groups than in the control
groups. Results from those who completed the study
were similar to those from the intention-to-treat analy-
sis. Treatment responders showed relevant improve-
ments in all outcome domains [20]. The only patient
characteristic predicting a positive outcome was past
abstinence-oriented treatment [21].
Eighty-two per cent of the responders in the experi-
mental groups deteriorated substantially during the
2 months following cessation of heroin co-prescription,
and the mean outcome scores returned to those before
entering the program [20].
The positive outcome of the study led to a parlia-
mentary decision in 2004 to increase the number of
treatment slots to 1000, to be situated in 11–15 cities.
However, only about 300 treatment slots in six cities
were actually set up, mainly because of financial prob-
lems. By 2008 there were eight specialist clinics pre-
scribing heroin to approximately 350 patients. The
centres have 25–70 treatment slots each. A further
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increase is intended, mainly with smaller centres having
25–30 slots.
Injectable and inhalable heroin were registered as a
substitution drug in the treatment of heroin dependence
in December 2006 by the Dutch Medicines Evaluation
Board. Heroin-assisted treatment is authorised for
chronic, treatment-resistant heroin addicts who could
not be stabilised satisfactorily in a methadone mainte-
nance program. New patients can be admitted. The
indication criteria are practically unchanged. In 2007
heroin-assisted treatment became acknowledged as a
regular treatment under special conditions.
In Germany, the largest randomised study on
heroin-assisted treatment started in 2002 and ended in
2005. Clinics were set up in seven cities and a total of
1032 patients were enrolled in the program (515 on
heroin maintenance). All received an intensive psycho-
social care program. The average daily dose of heroin
was 442 mg; after the induction phase dosage was
stable [22].
The design was a 4 ¥ 2 randomised multicentre
study with two target groups (methadone patients who
continue to inject heroin, and heroin addicts out of
treatment for at least 6 months) and four arms for each
target group (heroin vs. methadone, psychoeducation
vs. case management with motivational interviewing).
The study was divided into two phases:
Phase 1: in the first 12 months, a stratified 4 ¥ 2 ran-
domised controlled trial in order to examine the effects
of heroin prescribing as compared with methadone pre-
scribing under similar conditions.
Phase 2: follow-up study over 12 months in order to
investigate the long-term effects in the experimental
group; a randomly selected group of control patients
receives heroin prescription, the rest leave the study and
are offered regular treatment.
Special studies addressed criminological aspects,
economic aspects, neuropsychological issues, psychoso-
cial interventions, acceptability and implementation of
the project.
The findings showed better results for the heroin
group in regard to the criteria (improvement in somatic
or mental health of at least 20%; a major reduction of
street heroin use and no increase in cocaine consump-
tion). The differences are statistically significant. The
improvements from heroin-assisted treatment were
equal for both target groups (refractory methadone
patients, patients out of treatment) and for both types
of psychosocial intervention (psychoeducation, case
management) [22].
After 2 years, the heroin group showed highly signifi-
cant improvements in physical and mental health, while
illicit heroin and cocaine use also decreased signifi-
cantly [23].
Based on the evaluation results, the Registration
Authority (Bundesinstitut für Arzneimittel und Mediz-
inprodukte BfArM) decided in favour of a continuation
of heroin-assisted treatment on a routine basis, and
Parliament agreed to provide the necessary new legal
basis for a continuation in 2008.
In Spain, initiatives to set up trials with diamorphine
were taken in two of the Autonomous Regions—in
Andalusia and in Catalonia. During 2000–2001, these
initiatives were discussed in the Central Agency for
Drug Addiction. The authorities decided to allow the
trials, with the expectation that they would generate
new scientific insights, and to get approval of the Drug
and Pharmaceutical Control Office for registration of
diamorphine as a medicine. A clinical trial of heroin
maintenance therapy was authorised in 2001 [24].
A randomised controlled trial started in 2003 in
Granada and was completed in 2004. Sixty-two heroin
addicts were recruited, 31 in each group. The average
daily dose of heroin was 274.5 mg plus 42.7 mg metha-
done in the experimental group, while 105 mg metha-
done was prescribed in the control group. Both groups
received comprehensive clinical, psychological, social
and legal support.
The results showed significantly better results in the
experimental group, in regard to physical health, reduc-
tion of risk behaviour, reduction of drug use and of
involvement in crime [25].
The Council of Andalusia requested continued com-
passionate use for the 36 patients who participated in
their clinical trial. The Spanish Agency for Medicine
(an organisation under the Ministry of Health) gave its
consent and authorised these patients to receive heroin
for life.
In the UK, the Randomised Injecting Opioid Treat-
ment Trial recruited 127 opiate addicts who continued
to frequently inject illegal heroin despite being pre-
scribed substitute oral opiate-type drugs. These 127
patients were randomly allocated either to injectable
methadone or heroin for 6 months, or to continue on
oral methadone. If necessary doses were individually
adjusted to high levels (to 300 mg of oral methadone, to
200 mg of injectable methadone, to 900 mg of inject-
able heroin per day) to achieve maximal comfort and
suppression of illicit opiate use. Patients received
regular psychosocial support if needed. After the
6 months of the trial, patients were reassessed for the
most appropriate treatment, including possible inject-
able prescribing for those previously allocated to oral
methadone.
There was better retention in the groups receiving
injectables (88% in the heroin group, 81% in the
methadone group), in contrast to the group receiving
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oral methadone (69%), and a significantly better reduc-
tion in illegal heroin use in the heroin group. After
adjusting for other factors, 66% of the heroin group had
a good response to treatment (vs. 30% in the i.v. metha-
done group and 19% in the oral methadone group).
These findings were based on urine analysis differenti-
ating illegal heroin use from prescribed heroin [26].
In Canada, 251 heroin injectors who had not prof-
ited from at least two previous treatments were ran-
domised to injectable heroin (n = 115), oral methadone
(n = 111) or injectable hydromorphone (n = 25), and
assessed after 12 months; main outcome criteria were
retention and use of illicit drugs or other illegal activity.
The intention-to-treat analysis resulted in a signifi-
cantly better retention in the heroin group (88% vs.
54% in the methadone group) and reduction in illegal
use or activity (67% vs. 48%).There were some adverse
events, but limited to non-fatal overdoses and seizures
after injections [27].
A summary of findings on feasibility, outcome
and impact
The results from all the studies have been published
extensively, including 2 year and 6 year follow-up
results from the Swiss cohort [28,29], 2 year follow-up
results from Germany [23] and 4 year follow-up results
from the Netherlands [30]. Recent reviews provide
details [31,32]. A monograph on heroin-assisted treat-
ment is in preparation at EMCDDA, the European
Centre on Drugs and Drug Addiction in Lisbon.
Feasibility
Heroin-assisted treatment can be implemented with
good acceptance by patients, by law enforcement
authorities and—in the case of Swiss national
referenda—by the general public. The target group of
chronic, marginalised and treatment-resistant heroin
addicts could successfully be reached (for admission
criteria see Table 1)
Safety
Heroin-assisted treatment can be implemented without
undue risks for patients, staff and public order; under
the control conditions of the studies discussed here, no
diversion of prescribed substances to the illicit market
and no fatal overdose from prescribed heroin could be
found. Serious adverse effects occur, and can be well
managed. Cerebral undersaturation of oxygen, causing
convulsions and respiratory depression, was found
more frequently in heroin maintenance than in control
groups (in Switzerland, Germany, the UK and
Canada), but staff and patients learned to avoid this by
promoting physical activity after injections. Annual
mortality rates from all causes are below those of
Table 1. Admission criteria for heroin maintenance treatment
Criteria Switzerland Netherlands Germany Spain UK Canada
Minimal age (years) 18 25 25 18 18 25
Local residency
required
Yes >3 years >5 years — Yes >1 year
Diagnostic assessment ICD-10 DSM-IV ICD-10 ICD-10 DSM-IVR DSM-IV
Duration heroin
dependence
>2 years >5 years >5 years — >3 years >5 years








Yes Yes Yes Yes





If out of treatment >6 months
Informed consent Yes Yes Yes Yes Yes Yes
Randomisation
accepted
No Yes Yes Yes Yes Yes
Sources: Switzerland: 17, Netherlands: 19, Germany: 21, Spain: 24, UK: 25, Canada: 26. DSM-IV, Diagnostic Statistical Manual
4th edition; DSM-IVR, Diagnostic Statistical Manual revised 4th edition; ICD-10, International Classification of Diseases 10th
edition; MMT, Methadone Maintenance Treatment.
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untreated heroin addicts and of those in other treat-
ments [33].
Treatment effects
All treatment effects indicate an improvement in physi-
cal and mental health, a reduction of risk-taking behav-
iour (especially needle sharing), a reduction of crime
involvement and some improvement in social integra-
tion (although the stigma of heroin dependence is a
major obstacle). Significant positive effects are docu-
mented from all studies, at different time points
(Table 2). Positive effects persist over time after leaving
the program.
Patient satisfaction
Satisfaction is generally high; there were some com-
plaints concerning organisational details, but not the
treatment or the substance per se.
Impact on other treatment approaches
No negative effects on other treatment approaches
could be observed.Where data are available, they show
an overall increase in treatment availability, utilisation
and quality for heroin addicts during the implementa-
tion of heroin-assisted treatment.
Impact on public health and public order
Heroin-assisted treatment reduces the risk of blood-
borne infectious diseases and their transmission to
others. It reduces the role of heroin addicts in recruiting
new addicts, by a reduction of their involvement in drug
trafficking. Heroin-assisted treatment reduces the
crime involvement of patients, and the nuisance for the
public in general caused by addicts not in treatment.
Cost–benefit
The Swiss, the Dutch and the German experiments
have been evaluated economically; all with favourable
cost–benefit ratios [34–36].
Implications for drug policy
All these scientific projects had and have some features
in common: the model of maintaining heroin addicts on
supervised injections (or inhalation or oral applica-
tions) of pharmaceutical diamorphine, in the frame-
work of a comprehensive assessment and care program,
targeting specifically heroin addicts who are out of
treatment or who continued to use illicit heroin while
being on other treatments, including methadone main-
tenance. The idea is not to reach out to heroin addicts
in general, but to those otherwise not reachable, in a
perspective of public health and public order priorities
[37,38]. The treatment modality is not conceived as
replacing other forms of treatment.
Heroin prescription has moved from idea to experi-
mental project to routine treatment and is part of an
overall treatment network for heroin addiction in Swit-
zerland, the Netherlands, Germany and Denmark,
without known negative effects on other approaches
and on prevention. WHO made a cautious assessment
of this approach, in view of the limited experience and
the safety risks, especially when set up in less resourced
and well-organised health systems [39,40]. An early
Cochrane review came to similar conclusions [41],
while a recent one is still under discussion [42].
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